Study Shows Lumenate’s® Synergistic Power on Skin Structure and Collagen Protection
A preclinical study just published in Advances in Bioscience and Biotechnology demonstrates impressive benefits for skin structure when using Lycored Lumenate® combined with ceramides. The results show that combining even low concentrations of ceramides with Lumenate produces synergistic effects within…
Therap Services Debuts Secure Document Signing Module (SDS) with Enhanced Digital Security and Efficiency in Streamlining Healthcare Signatures
Therap Services, the national leader in providing HIPAA-compliant electronic documentation solutions to organizations and caregivers in the Long-Term Services and Supports (LTSS), Home and Community-Based Services (HCBS) and broader human services setting, is excited to announce the launch of its…
Koning Health Achieves UAE Regulatory Clearance, Paving the Way for Breast CT Commercialization in the Middle East
Koning Health, a pioneering medical imaging company, is thrilled to announce that it has received regulatory clearance from the Federal Authority for Nuclear Regulation (FANR) in the United Arab Emirates (UAE), marking a significant milestone in the company’s expansion and its commitment…
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting the significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead, late-clinical stage product candidate and innovative therapeutic and diagnostic products, today highlighted…
Philips extends leadership in virtually helium-free MRI with more than 1,000 systems installed, expanding patient access worldwide
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced a significant milestone as it expands access to virtually helium-free [1] MRI to more patients in more places, with more than 1,000 systems now installed worldwide. As…
Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia
Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that the U.S. Food and Drug Administration (FDA) has accepted the…
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers
Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the completion of the clinical stage of its Phase 1, single ascending dose escalation trial of TNX-1500 (Fc-modified humanized anti-CD40L…
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial
Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced the publication of a peer-reviewed article titled, “A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity” in…
CG Oncology Announces First Patient Dosed in PIVOT-006 Phase 3 Clinical Trial of Cretostimogene in Intermediate-risk Non-Muscle Invasive Bladder Cancer
CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the first patient has been dosed in the PIVOT-006 Phase 3 clinical…
Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that Memorial Sloan Kettering Cancer Center has joined MD Anderson Cancer Center in enrolling patients in a Phase 1/2 clinical trial evaluating IMUNON’s IMNN-001 in…
